(-0.22%) 5 011.12 points
(0.06%) 37 775 points
(-0.52%) 15 601 points
(3.86%) $85.92
(1.14%) $1.777
(0.74%) $2 415.80
(0.85%) $28.62
(-0.07%) $953.80
(0.27%) $0.942
(0.26%) $11.07
(0.35%) $0.807
(0.05%) $93.95
Live Chart Being Loaded With Signals
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide...
Stats | |
---|---|
Today's Volume | 304.00 |
Average Volume | 176 420 |
Market Cap | 20.23M |
EPS | $0 ( 2024-02-07 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.400 |
ATR14 | $0.00100 (5.26%) |
Volume Correlation
Pharmaxis Ltd Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Pharmaxis Ltd Correlation - Currency/Commodity
Pharmaxis Ltd Financials
Annual | 2022 |
Revenue: | $5.77M |
Gross Profit: | $3.06M (53.06 %) |
EPS: | $-0.0173 |
Q1 | 2023 |
Revenue: | $771 000 |
Gross Profit: | $-925 000 (-119.97 %) |
EPS: | $-0.00850 |
Q4 | 2022 |
Revenue: | $5.04M |
Gross Profit: | $1.53M (30.31 %) |
EPS: | $-0.00450 |
Q3 | 2022 |
Revenue: | $5.04M |
Gross Profit: | $1.53M (30.31 %) |
EPS: | $-0.00450 |
Financial Reports:
No articles found.
Pharmaxis Ltd
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of oral pan-lysyl oxidase inhibitors (LOX) targeting myelofibrosis and other cancers; topical pan-LOX inhibitors targeting skin scarring after events, such as accidents, surgery,and burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases, including kidney fibrosis, pulmonary fibrosis, liver fibrosis, and cardiac fibrosis; and semicarbazide-sensitive amine oxidase for neuro inflammatory diseases. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators